GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » Shiller PE Ratio

Adverum Biotechnologies (STU:AVU0) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Adverum Biotechnologies Shiller PE Ratio Historical Data

The historical data trend for Adverum Biotechnologies's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Shiller PE Ratio Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adverum Biotechnologies's Shiller PE Ratio

For the Biotechnology subindustry, Adverum Biotechnologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Shiller PE Ratio falls into.



Adverum Biotechnologies Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Adverum Biotechnologies's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Adverum Biotechnologies's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Adverum Biotechnologies Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -2.949 100.560 -3.864
201409 -3.880 100.428 -5.091
201412 -3.704 99.070 -4.927
201503 -3.511 99.621 -4.644
201506 -3.386 100.684 -4.432
201509 -4.900 100.392 -6.432
201512 -5.003 99.792 -6.606
201603 -5.119 100.470 -6.714
201606 -15.664 101.688 -20.299
201609 -3.118 101.861 -4.034
201612 -5.119 101.863 -6.622
201703 -3.553 102.862 -4.552
201706 -2.403 103.349 -3.064
201709 -2.685 104.136 -3.398
201712 -2.704 104.011 -3.426
201803 -2.433 105.290 -3.045
201806 -2.568 106.317 -3.183
201809 -2.914 106.507 -3.605
201812 -2.110 105.998 -2.623
201903 -2.036 107.251 -2.502
201906 -2.036 108.070 -2.483
201909 -2.270 108.329 -2.761
201912 -2.700 108.420 -3.282
202003 -2.805 108.902 -3.394
202006 -3.197 108.767 -3.873
202009 -2.632 109.815 -3.158
202012 -3.206 109.897 -3.844
202103 -2.436 111.754 -2.872
202106 -3.735 114.631 -4.294
202109 -3.315 115.734 -3.774
202112 -3.098 117.630 -3.471
202203 -3.450 121.301 -3.748
202206 -4.162 125.017 -4.387
202209 -4.040 125.227 -4.251
202212 -3.115 125.222 -3.278
202303 -2.709 127.348 -2.803
202306 -2.861 128.729 -2.929
202309 -3.092 129.860 -3.138
202312 -2.109 129.419 -2.147
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adverum Biotechnologies  (STU:AVU0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Adverum Biotechnologies Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (STU:AVU0) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines